Welcome to our dedicated page for Cuprina Holdings (Cayman) SEC filings (Ticker: CUPR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Cuprina Holdings (Cayman) Limited (CUPR) SEC filings page provides access to the company’s regulatory reports as a foreign private issuer listed on The Nasdaq Capital Market. Cuprina files current reports on Form 6-K under the Securities Exchange Act of 1934, which include press releases and other information furnished to investors.
Recent Form 6-K filings referenced by the company include reports furnishing press releases about its joint venture with Aiodine Laboratory to develop and market a novel iodine-based wound care and antiseptic solution, its exclusive licensing of a UNIDO/GEF-demonstrated medical waste recycling technology for Singapore and other Southeast Asian markets, and its update on research collaborations with Singapore-based institutes on bullfrog-derived collagen peptides. Other 6-Ks report on corporate developments such as the appointment of a new Medical and Scientific Director and the licensing of an FDA-cleared medical maggot product, as well as changes in the company’s independent registered public accounting firm.
Cuprina also uses Form 6-K to disclose matters such as the resignation of certain officers and to furnish press releases related to operational and research milestones. In addition, the company has directed investors to its 6-K filing for detailed financial results for specific periods. Through these filings, investors can review information on chronic wound therapies, infertility-related initiatives, medical waste recycling activities and cosmeceutical research that the company chooses to furnish to the U.S. Securities and Exchange Commission.
On this page, users can track new 6-K submissions for CUPR as they are made available from EDGAR, and use AI-powered summaries to quickly understand the key points, including financial disclosures, auditor changes, strategic agreements and other reportable events described by Cuprina.
Cuprina Holdings (Cayman) Limited reported that it issued a press release on November 18, 2025 announcing the formation of a joint venture company with Aiodine Laboratory. The joint venture is intended to develop and market a novel iodine-based solution as a new wound care therapy. The press release describing this collaboration is included as Exhibit 99.1 to this Form 6-K.
Cuprina Holdings (CUPR) reported a change in its independent registered public accounting firm. The board dismissed Kreit & Chiu CPA LLP effective October 15, 2025, and appointed J&S Associate PLT as successor auditor to audit the consolidated financial statements for the fiscal year ending December 31, 2025. The audit committee approved the appointment.
K&C’s audit reports for 2024 and 2023 contained no adverse opinions or disclaimers and were not qualified or modified. The company stated there were no disagreements with K&C on accounting principles, disclosure, or audit scope during the two most recent fiscal years and through October 14, 2025, and no reportable events as defined in Item 16F(a)(1)(v) of Form 20-F. A letter from K&C addressing the disclosure was filed as an exhibit.
Cuprina Holdings (Cayman) Limited filed a Form 6-K to disclose a management change and related IP development step. The company announced that Dr. Ronald A. Sherman will become its Medical & Scientific Director effective 15 Sep 2025. Concurrently, Cuprina signed a licensing agreement with Dr. Sherman; however, the filing does not provide economic terms, duration, or scope of the licensed assets. No financial results, guidance, or other operational updates were included.
Cuprina Holdings (Cayman) Limited (CUPR) has filed a Form 6-K announcing the resignation of Mr. Baptista Carl Marc from his positions as Director and Chief Technology Officer, effective 30 June 2025. The company states that Mr. Baptista is leaving to pursue other business opportunities and that the departure is not due to any disagreement with the company on operational or governance matters. No successor or interim CTO has been named in the filing, and no additional financial information or strategic updates were provided.
Cuprina Holdings (Cayman) Limited filed a Form 6-K on 30 June 2025. The sole purpose of the submission is to furnish a press release (Exhibit 99.1) that offers an update on the company’s research studies conducted with three leading education institutes. Apart from confirming that the press release was issued and attaching it as an exhibit, the filing contains no financial statements, earnings data, major transactions, or other material disclosures. The document is therefore primarily administrative, indicating ongoing collaboration activity while fulfilling SEC disclosure requirements for foreign private issuers.
FAQ
What is the current stock price of Cuprina Holdings (Cayman) (CUPR)?
What is the market cap of Cuprina Holdings (Cayman) (CUPR)?
